Artelo Biosciences, INC. 8-K Filing
Ticker: ARTL · Form: 8-K · Filed: Apr 7, 2026 · CIK: 0001621221
Sentiment: neutral
Filing Stats: 780 words · 3 min read · ~3 pages · Grade level 13.1 · Accepted 2026-04-07 08:00:10
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ARTL The Nasdaq Stock Mar
- $2.5 million — intain stockholders' equity of at least $2.5 million for continued listing (the "Equity Rule
Filing Documents
- artl_8k.htm (8-K) — 28KB
- artl_ex991.htm (EX-99.1) — 7KB
- artl_ex991img2.jpg (GRAPHIC) — 5KB
- 0001640334-26-000662.txt ( ) — 161KB
- artl-20260406.xsd (EX-101.SCH) — 5KB
- artl-20260406_lab.xml (EX-101.LAB) — 15KB
- artl-20260406_cal.xml (EX-101.CAL) — 1KB
- artl-20260406_pre.xml (EX-101.PRE) — 9KB
- artl-20260406_def.xml (EX-101.DEF) — 2KB
- artl_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On April 6, 2026, Artelo Biosciences, Inc. (the "Company") received a letter from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires that the Company maintain stockholders' equity of at least $2.5 million for continued listing (the "Equity Rule"), and Nasdaq Listing Rule 5620(a), which requires companies listed on Nasdaq to hold an annual meeting of shareholders no later than one year after the end of the Company's fiscal year-end (the "Annual Meeting Rule"), further to a letter from the Nasdaq Hearings Panel (the "Panel") dated February 2, 2026, which granted the Company an exception to cure both listing deficiencies. Pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor through April 6, 2027. If, within that one-year monitoring period, the Listing Qualifications Department staff (the "Staff") finds the Company again out of compliance with the Equity Rule that was the subject of the exception then, notwithstanding Nasdaq Listing Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and the Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the Company be afforded an applicable cure or compliance period pursuant to Nasdaq Listing Rule 5810(c)(3). Instead, Staff will issue a Delist Determination Letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened Hearings Panel if the initial Panel is unavailable. The Company will have the opportunity to respond/present to the Hearings Panel as provided by Nasdaq Listing Rule 5815(d)(4)(C), and the Company's securities may be at that time delisted from Nasdaq. On April 7, 2026, the Company issued a press release announcing that it regained compliance
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated April 7, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 7, 2026 ARTELO BIOSCIENCES, INC. /s/ Gregory D. Gorgas Name: Gregory D. Gorgas Title: Chief Executive Officer and President 3